BUZZ-Vivos Therapeutics rises on FDA approval for pediatric sleep apnea device

Reuters09-18

** Shares of medtech firm Vivos Therapeutics rise 24.4% to five-month high of $3.48

** Co says U.S. FDA has granted clearance for its sleep apnea device

** The device is designed to reduce nighttime snoring and treat moderate to severe obstructive sleep apnea in children aged 6 to 17

** Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder with symptoms including snoring and daytime fatigue

** The clearance was based on a study that showed the device reduced snoring by 58% in pediatric patients and also reduced other OSA symptoms such as fatigue and lack of attention

** There were no safety concerns reported in the study - co

** Including session moves, stock down 71.6% YTD

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment